Cambrex Corporation has announced plans to start making high potency APIs at its plant in Milan, Italy citing impending patent losses for small molecule drugs as an opportunity.
Cambrex Corporation says higher demand for APIs for controlled substances and branded drugs drove Q2 growth and confirms it is on the lookout for acquisitions.
High potency APIs are becoming a key focus of the pharmaceutical business, with drug makers from all areas racing to establish a foothold in the market.
Contract pharmaceutical services supplier Arch Pharmalabs has
purchased a 70 per cent stake in fellow India-based active
pharmaceutical supplier (API) Benzochem Lifesciences for around Rs
1bn ($23m), strengthening its position in...